ARS Pharmaceuticals, Inc. SPRY Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
Based on the most recent quarter.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s current ratio?
- ARS Pharmaceuticals, Inc. (SPRY) reported current ratio of 4.9× in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s current ratio changed year-over-year?
- ARS Pharmaceuticals, Inc.'s current ratio decreased by 55.1% year-over-year, from 11× to 4.9×.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s current ratio?
- Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s current ratio has grown at a -29.1% compound annual growth rate (CAGR), from 40.7× to 7.3×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.